Nasdaq: MCRB

Seres Therapeutics, Inc.

Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis.

New insights into the human microbiome are fundamentally reshaping how we understand and treat a wide range of diseases, creating new possibilities for patients not served by current approaches. We are a clinical biopharmaceutical company with a powerful platform to discover and develop drugs to treat diseases in multiple areas of medicine that arise from dysbiosis.